Bruce Power announced on July 20 that it has signed a memorandum of understanding with Isogen, a joint venture of Framatome and Toronto-based Kinectrics, and BWXT ITG Canada to advance feasibility work for the production of molybdenum-99. Mo-99 is the radioisotope most commonly used in nuclear medicine for diagnostic imaging and the detection of disease, along with other medical isotopes that are growing in demand.

According to the company, the partnership will work to leverage existing production systems being developed to produce lutetium-177 starting in 2022 at Bruce Power and BWXT’s isotope processing facilities in Kanata, Ontario, along with Kinectrics’ facilities in Teeswater and Etobicoke.

To watch the webinar please visit:

https://www.ans.org/news/article-378/bruce-power-to-work-with-isogen-bwxt-on-isotopes/